Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis.
- Published in:
- CNS Drugs, 2024, v. 38, n. 3, p. 205, doi. 10.1007/s40263-024-01072-5
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2024 AND VI 38 AND IP 3
Results: 6
1
2
Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data.
- Published in:
- CNS Drugs, 2024, v. 38, n. 3, p. 163, doi. 10.1007/s40263-024-01071-6
- By:
- Publication type:
- Article
3
Unmet Needs in Psychodermatology: A Narrative Review.
- Published in:
- CNS Drugs, 2024, v. 38, n. 3, p. 193, doi. 10.1007/s40263-024-01068-1
- By:
- Publication type:
- Article
4
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
- Published in:
- CNS Drugs, 2024, v. 38, n. 3, p. 169, doi. 10.1007/s40263-024-01067-2
- By:
- Publication type:
- Article
5
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
- Published in:
- CNS Drugs, 2024, v. 38, n. 3, p. 231, doi. 10.1007/s40263-024-01066-3
- By:
- Publication type:
- Article
6
Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center.
- Published in:
- CNS Drugs, 2024, v. 38, n. 3, p. 225, doi. 10.1007/s40263-024-01065-4
- By:
- Publication type:
- Article